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Chemical investigations of the chemistry of Fijian reef systems have yielded the 
discovery of an iodinated diterpene-benzoate produced by the Fijian red macroalga 
Callophycus sp. Through the use of bioassay guided fractionation, NMR and mass 
spectrometric-based structural elucidation, diiodocallophycoic acid (1) was successfully 
isolated and structurally characterized. This novel secondary metabolite was found to 
contain two highly unusual exocyclic iodinated olefins and demonstrated moderate 
biological activity against methicillin resistant Staphylococcus aureus (MRSA) with an 
MIC of 3.9 μg/mL.  
 






















A critical element in the success of humans against the threat of disease has been 
the adoption of medicinal remedies from natural sources, primarily terrestrial plant 
species.1 Based on these early practices, natural product chemists have sought to isolate 
and characterize the molecular constituents responsible for observed biological activities 
of natural extracts.  
Eliciting a wide range of pharmacological effects, natural product based drugs 
have advanced the treatment of human disease. The clinical significance of natural 
therapeutics is evident given that natural product based carbon skeletons and 
pharmacophores have inspired the design of 74% of biologically active compounds and 
constitute the majority of anti-infective (69%) and anti-cancer agents (75%).2  The wide 
range of medical applications and historical significance of natural products and their 
derivatives are exemplified by:  penicillin (antibacterial agent); paclitaxel (Taxol®; 
ovarian and breast cancer treatment); morphine (analgesic); artemisinin and quinine  
(malaria treatments).2 
  Investigations of natural product biological activity and their interactions with 
cellular machinery have enhanced our understanding of developmental and cancer 
biology. The effects of the teratogen cyclopamine (2) (Figure 2) 3, 4, produced by 
Veratrum californicum, on fetal lamb susceptibility to the congenital disease cyclopia 
were found to be dependent on the gestational period in which the mother consumed V. 





the inhibition of the sonic hedgehog developmental pathway6 via binding of cyclopamine 
to the integrand smoothened.7  
 
Figure 2 – Reported structures of cyclopamine and vismodegib.  
 
Now implemented as a therapeutic target in the treatment of various hedgehog associated 
cancers, such as basal cell carcinoma8, synthetic studies of smoothened inhibitors led to 
the discovery of the marketed chemotherapeutic vismodegib (3) (Figure 2).9, 10  
The use of natural products as therapeutics can be attributed in part to their 
evolutionary history and the ecological interactions resulting from their development.11 
While it should be noted that human exploitation of natural products has no bearing on 
their native functions or evolutionary history, microbial defensive compounds have had 
dramatic impacts on human health.  In the case of soil dwelling microbes such as 
members of the Streptomyces genus, the up-regulation of defensive compounds (i.e. 
antibiotics) is hypothesized to contribute to periods of intensified competition when 
nutrients are limited.12 Evidence for such claims can be drawn from members of the 
Streptomyces genus through the production of streptogramin antimicrobial compounds.13 
Classified as type A or B, members of this family of molecules are coproduced and act 
synergistically to inhibit bacterial peptide translation via binding to ribosomal active 





















production of the structurally unrelated pristinamycins A (4) and B (5) (Figure 3) were 
found to be clustered on the same chromosome over a 200 kb region. Based on these 
results, it has been hypothesized that the utilization of two independent metabolic 
pathways evolved based on the constant presence of competitors with resistance to one of 
the two components.13, 18  
 
Figure 3 – Reported examples of streptogramins isolated from S. pristinaespralis.  
 
 
The rise of drug resistant bacterial populations represents a constant threat to the 
global human population. Drug resistant strains, such as methicillin resistant 
Staphylococcus aureus (MRSA), were first documented in the early 1950’s19 and have 
since been observed in a wide spectrum of infections ranging from skin lesions to septic 
arthritis.20 Driven in part by the improper usage of antibiotics (e.g. patient failure to finish 
a regimen) bacterial populations have demonstrated remarkable adaptability.21, 22 The  
1950’s implementation of erythromycin as a treatment for S. aureus saw drug resistant 






























Boston City Hospital.23 The rise of bacterial resistance has classically been attributed to 
mutations within bacterial resistance genes (r genes) resulting in the degradation or 
inhibition of prescribed treatments.21, 22  β-lactam based drugs, such as penicillins, which 
generally act to disrupt cell wall biosynthesis are especially susceptible to hydrolytic 
degradation via  β-lactamases.24 The accumulated discovery of over 1,000 β-actamases 
(native and mutant forms) and their propensities for horizontal gene transfer via 
conjugation has highlighted the dangers of bacterial r gene plasticity and 
communicability.11, 25 Studies of vancomycin have revealed the periodic evolution of 
resistant strains26 based on the increase of minimal inhibitory concentration (MIC) values 
from ≤ 1 to ≥1.5 μg/mL.27 The threat of emerging, untreatable bacterial strains has 
necessitated the pursuit of alternative antibiotic sources. 
In light of evolutionary arguments and the high degree of biodiversity in marine 
ecosystems28, 29, one could predict that the frequency and complexity of ecological 
interactions within such environments would result in a wide range of natural products 
stemming from diverse metabolic pathways.30 Studies of marine sponges have resulted in 
the discovery of numerous structurally diverse and biologically active compounds,31 such 
as the polyether macrolide  halichondrin B32, now marketed as the derivatized  
chemotherapeutic Halaven®.33 The metabolic complexity of marine sponge taxa has 
classically been attributed to their interactions with symbiotic microbes.34, 31 This 
hypothesis has been further validated through the identification of two chemically distinct 
microbial symbiotes, ubiquitous in the marine sponge Theonella swinhoei. Genetic 
analysis confirmed that these microbial communities were responsible for the production 






Studies of Fijian marine organisms have served to demonstrate that complex 
ecological interactions could serve as a hallmark of metabolic diversity, leading to novel 
natural products. In the case of red macroalgal genera, such as Peyssonnelia and 
Callophycus, susceptibility to fungal invasion may have selected for the development of 
surface confined terpenoids, serving as antimicrobial agents.36, 37 Additional 
investigations into Callophycus spp. have revealed a host of novel halogenated macrolide 
and non-macrolide diterpene shikimates. 38, 39, 40, 41  Bromophycolide P (6) 42 and 
callophycoic acid G (7) 40, 41 (Figure 4) demonstrated anti-MRSA activity with MICs of 
1.4 and 1.6 μg/mL respectively. Further work with Callophycus sp. collection G-0807, 
resulted in the discovery of five new halogenated diterpene-benzoic acid metabolites, 
bromophycoic acids A-E41. Bromophycoic acid A (8) was notably effective against 
MRSA, having an MIC of 1.6 μg/mL, comparable to currently marketed antibiotics. 43 
 
Figure 4 –  Reported biologically active natural products from Callophycus spp.  
 
  While past assessments of Callophycus sp. collection G-0807 have successfully 
resulted in the identification of five bromophycoic acid analogs, unpublished 

























related metabolites. Due to the comparability of known bromophycoic acid A to current 
treatment options and past instances of metabolite analog diversity exhibited by the 
Callophycus genus 38, 39, 40, 41, this study sought to discover novel secondary metabolites 
demonstrating anti-MRSA activity. In order to isolate novel analogs from previously 
generated algal extracts, a combination of biological assays and chromatographic 
techniques—thin layer chromatography (TLC), high performance liquid chromatography 
(HPLC), liquid chromatography coupled to mass spectrometry (LC-MS) and solid phase 
extraction (SPE)—were utilized in a process known as bioassay guided fraction. 
Structural elucidation of the isolated active species required the use of various 
spectrometric and spectroscopic techniques, including 1H & 13C nuclear magnetic 








Biological material  
Collection G-0807 was procured on April 6th, 2010 between 10 and 20 m on 
channel walls and the reef slope near the Mango Bay Resort, Viti Levu, Fiji (18° 14’ 12’’ 
S, 177° 46’ 48’’ E). This collection was identified as Callophycus sp. through a series of 
18S rDNA analyses and morphological comparisons as previously described. 44 Voucher 
specimens were preserved in aqueous formaldehyde and stored at the University of the 
South Pacific.  
General Procedures  
  HPLC based fractionations and purifications were conducted using a Waters 1525 
pump coupled to a Waters 2487 dual-wavelength absorbance detector set for 254 & 277 
nm and operated via Waters Empower Version 3.20 software. All LC-MS based analyses 
utilized a Waters 2695 Separation Module coupled to a Waters 2996 photodiode-array 
UV detector and a Micromass ZQ 2000 mass spectrometer with electrospray ionization in 
negative mode. Optical rotations were collected on a Jasco DIP 360 Digital Polarimeter.  
LC-MS associated chromatographic separations were performed using a Grace Altima 
C18 -silica column (3 μm, 2.1 x 100 mm) and gradient mobile phase of 70% to 95% 
aqueous acetonitrile containing 0.1% aqueous acetic acid over 30 min at a flow rate of 1 
mL/min . High-resolution mass spectrometry was conducted on a LTQ OrbiTrap in 





  NMR spectra (1H, DEPT-135, HMBC, HSQC, COSY and ROESY) were 
obtained on a Bruker DRX-500 instrument, equipped with either a 5 mm inverse or 
broadband probe. All HPLC purifications were directed through 1H NMR spectroscopy in 
place of traditional bioassay guided fractionation in order to monitor structurally relevant 
compounds based on published spectral data.41 All solvents were either HPLC or Optima 
grade (Fisher Scientific Co.) and NMR solvents were purchased from Cambridge Isotope 
Laboratories.  
Isolation  
  A 250 mL equivalent of frozen algal mass corresponding to Callophycus sp. 
collection G-0807 was thawed and  exhaustively extracted with methanol followed by 1:1 
methanol/dichloromethane. Filtered extracts were pooled and reduced in vacuo. The 
resulting crude extract was first partitioned against hexanes and methanol/water (9:1), 
which was followed by an adjustment of the methanol/water fraction with water to 3:2 
methanol/water and partitioned against chloroform. The three resulting fractions were 
reduced in vacuo to dryness.  The chloroform fraction was then fractionated by C18-silica 
flash chromatography (Supelco Envi-18, 10g) using a stepwise gradient from 70% 
aqueous methanol to 100% methanol to generate 11 fractions. The generated 11 fractions 
were combined based on TLC yielding 4 fractions. Based on LC-MS data, the relevant 
fraction was further purified via HPLC using a Grace Alltima C18-silica column (5μ, 10 x 
250 mm) with a gradient of 10% aqueous methanol with 0.1% formic acid to 100% 
methanol with 0.1% formic acid over 20 min at a flow rate of 3 mL/min. The relevant 
sub-fraction was further purified by HPLC on a Grace Altima C18-silica column (5 μm, 





over 26 min at 3 mL/min. The relevant fraction was further purified via HPLC using a 
Phenomenex Phenyl Hexyl column (5 μm, 9.4 x 250 mm) with a gradient from 70% 















  Extracts from Callophycus sp. collection G-0807 were found to contain the novel 
diterpene benzoate diiodocallophycoic acid  (1) exhibiting notable structural diversity and 
moderated biological activity against MRSA (MIC 3.9 μg/mL) and VREF (MIC 7.8 
μg/mL) (Table 1). Diiodocallophycoic acid (1) was found to exhibit [α]D25 -1.9x10-1 
(4.0x10-4 g/mL) and an HRESI [M-H]- of m/z of 816.8888 with an isotopic peak intensity 
ratio of 1:3:1, indicative of two bromine atoms. The molecular formula corresponding to 
this mass was determined to be C27H34Br2I2O3, (Δ= 0.27 ppm) consistent with a diterpene-
benzoate carbon skeleton, as demonstrated by previous molecules from the genus of 
macroalgae. 41          
Table 1 – Biological Assay Data for  1 
	   	   	  	  	   Antibacterial	  
	  	   MIC	  a	  
	  	   (μg/mL)	  
	  	   MRSA	   VREF	  
Diiodocallophycoic	  
Acid	  (1)	   3.9	   7.8	  
 
aMRSA= methicillin resistant Staphylococcus aureus; VREF= vanomycin resistant 
Enterococcus facium 	  






The observed aromatic protons associated with C-17 (δ 128.7), C-18 (δ 114.4), and 
C-4 (δ 125.6) (Table 1) were found to be indicative of a tri-substituted aromatic ring 
based on the singlet at δ 7.69, doublet at δ 6.86 (J= 8.4 Hz) and doublet of doublets at δ 
7.60 (J= 8.4, 1.9 Hz) (Figure 5). Further inspection of previously reported callophycoic 
acids 40, bromophycolides 39, 45, 46 and bromophycoic acids 41 all strongly pointed to the 
presence of a benzoate moiety. The previously described J coupling(s) observed between 
protons at δ 7.60 and δ 6.85 allowed for the assignments of C-17 and C-18. The 
assignment of C-1 (δ 168.1) was first inferred based upon the highly deshielded carbon 
resonance indicative of a carbonyl moiety. The orientation of the carbonyl was 
established with respect to C-17 (ortho) and C-4 (meta) due to HMBC correlations from 
H-17 (δ 7.60) and H-3 (δ 7.69) to the carbonyl center C-1.  
 
Figure 5  --  Key HMBC (solid single headed  arrows) and COSY (bolded lines) correlations 
















These assignments were further supported by reciprocal HMBC correlations from H-3 to 
C-17 and from H-17 to C-3. Due to the favorability of three bond HMBC correlations in 
aromatic systems, C-2 (δ 121.2) and C-4 (δ 125.6) were assigned based on correlations 
from H-18 (δ 6.86). Due to the resonance of a proton at δ 10.41 exhibiting HBMC 
correlations to C-4 and C-19, the presence of a phenol was inferred, accounting for the 
last oxygen atom. The assignment of C-19 (δ 159.1) as the phenolic carbon was 
determined based on HMBC correlations from both H-17 and the phenolic proton at δ 
10.41. The assignment of C-5 (δ 26.1) was based on HMBC correlations from H-3 to this 
carbon and H-5a (δ 2.60) to C-19, bridging the two aromatic and aliphatic.  
The second ring system was characterized via the observed methyl singlet at δ 
0.85 corresponding to Me-24 (δ 17.5), which exhibited HMBC correlations to C-6 (δ 
48.7), C-7 (δ 44.3) and C-23 (δ 62.7) (Figure 6). The inclusion of bromine to C-23 was 
rationalized based on the down field resonance of this carbon (δ 62.7) and its associated 
proton H-23 (δ 4.80). C-22 (δ 33.4) was then assigned via COSY correlations between 
H-23 and both H-22a (δ 1.94) and H-22b (δ 2.20), consistent with the observed 






Figure 6 --  Key HMBC (solid single headed  arrows; from proton to carbon) and COSY (bolded lines; J 
coupling) correlations.   
An additional COSY correlation between H-22a and H-21b (δ 2.60) allowed for the 
assignment of C-21 (δ 35.9). The assignment of the exocyclic olefin corresponding to C-
27 (δ 75.6) and C-20 (δ 146.6) was facilitated by HMBC correlations from the proton H-
27 (δ 5.95; singlet) to  C-20, C-21 and C-6. It was determined that the relatively up-field 
chemical shift of C-27 was confirmed based on published results. 47 The two-carbon 
bridge between the two isoprenoid rings consisting of C-8 (δ 37.5) and C-9 (δ 18.4) was 
elucidated based on an HMBC correlation from Me-24 to C-8 (δ 37.5) and a COSY 
correlation between H-8a (δ 1.35) and H-9 (δ 1.73). An additional COSY correlation 
between H-9 and H-10 (δ 2.05) linked the two aliphatic ring systems. An inspection of 
the 1H NMR data indicated the presence of two methyl singlets at δ 1.16 and δ 0.85 
corresponding to Me-16 (δ 27.5) and Me-25 (δ 17.5), respectively. HMBC correlations 
between these methyl groups and the quaternary carbon C-15 (δ 41.7) established a 


















HMBC correlations from both Me-16 and Me-25. Based on pervious carbon and proton 
resonance arguments the final bromine atom was assigned to C-14. COSY correlations 
between H-14 (δ 4.41) and H-13b (δ 2.20), as well as H-13a (δ 1.84) and H-12b (δ 2.60) 
facilitated the assignments of C- 13 (δ 33.8) and C-12 (δ 35.9) respectively. Utilizing the 
previous rationale, an additional exocyclic olefin moiety, consisting of C-11 (δ 147.7) 
and C-26 (δ 74.5) was identified and further supported by HMBC correlations from H-26 
(δ 6.02) to both C-11 and C-10. 
Table 2 –13C and 1H NMR Spectroscopic Data for 1 (500 MHz; DMSO-d6)a 
Carbon no.  δ 13C δ 1H (JH,H) 
1 167.2 
 2 121.2 
 3 131.0 7.69 d (1.9) 
4 125.6 
 5 25.3 2.60 m 
  
2.93 dd (12.1,10.8) 
6 48.7 2.93 m 
7 44.3 
 8 37.5 1.35 dt (16.2,7.1) 
  
1.56 m 
9 18.4 1.73 m 
10 54.8 2.05 dd (6.7,5.8) 
11 147.7 
 12 35.9 2.13 td (12.3, 4.2) 
  
2.60 m 
13 33.8 1.84 m 
  
2.2 m 
14 65.9 4.41 dd (10.2, 4.2) 
15 41.7 
 16 27.5 1.16 s 
17 128.7 7.60 dd (8.4, 1.9) 
















23 62.7 4.80 dd (10.8, 4.2) 
24 17.5 0.85 s 
25 17.5 0.85 s 
26 74.5 6.02 s 




a 13C and 1H NMR chemical shifts for 1 were inferred by DEPT-135, HSQC, and HMBC 
experiments rather than by a 13C NMR spectrum.  
The relative stereochemistry of 1 was assessed based ROESY NMR data and 
associated NOE signals. The elucidation of stereocenters C-6 (δ 48.7), C-7 (δ 44.3) and 
C-23 (δ 62.7) was initially facilitated through the establishment of two distinct molecular 
faces (Figure 7). The lower face was deduced based on NOE signals between Me-24 (δ 
0.85) and H-22a (δ1.94), which oriented both constituents on a common ring face axial to 







Figure 7 – Relevant NOEs for the first the assignment of stereogenic centers C-6, C-7 and C-23  
Pairwise NOE signals between H-21a (δ 2.13), H-23 (δ 4.80) and H-6 (δ 2.93), 
indicative of 1,3 diaxial interactions, allowed for the orientation of these protons on the 
upper ring face. This determination was suggested by a lack of NOEs between Me-24 and 
these protons and was solidified based on NOE signals between H-23 and both H-8b (δ 
1.56) and H-9 (δ 1.73). Thus, C-6, C-7 and C-23 were found to be in R configurations. 
The E assignment of the excocyclic olefin was confirmed via two NOE(s) between H-27 
(δ 5.95), the aromatic proton H-3 (δ 7.69) and the H-5b (δ 2.93). While H-6 (δ 2.93) and 
H-5a (δ 2.93) are notably equivalent protons, a lack of NOEs between H-27 and H-21a or 
H-21b further supported the assignment.  
 In light of carbon resonances, Me-16 (δ 27.5) was found to be equatorial relative 
to its germinal partner Me-25 (δ 17.5) (Figure 8). NOE signals between H-14 (δ 4.41) 
and both H-10 (δ 2.05) and H-12a (δ 2.13), indicative of a common molecular face, 
along with correlations between Me-16 (δ 1.16; equatorial) and H-10, lead to the S 
































assigned to the S configuration based on NOE correlations between H-13a (δ 1.84) and 
both H-9 (δ 1.73) and Me-25 (δ 0.85; axial) in addition to a correlation between Me-16 
and H-10 (δ 2.05). The E isomer assignment of the exocyclic olefin was notably 
ambiguous based upon within-ring NOE correlations and was thus determined through 
conformational arguments and  (see Figure 9).    
 
Figure 8 –Relevant NOEs for the assignment of stereogenic centers C-10 and C-14  
Conformational information derived from the ROESY spectrum allowed for the 
prediction of two possible epimers of 1. NOE correlations between the aromatic proton 
H-3 (δ 7.69) and both vinylic protons H-27 (δ 5.95) and H-26 (δ 6.02) (Figure 9) 




























Figure 9 --   Conformational analysis of 1 based on observed NOEs and the two possible epimers reflected 
by this data.  
Mutual NOE correlations between H-26, H-8b, and H-5a (δ 6.02, 1.56, and 2.60, 
respectively) established a mutual orientation for these protons, which was further 
supported by the lack of NOEs among H-5b, H-26 and H-8a (δ 1.35). These NOE 
correlations also fixed the C-26 olefin geometry as the E-isomer. Similarly, mutual NOE 
correlations between Me-16 (δ 1.16; equatorial), H-8a (δ 1.35), and H-23 (δ 4.80) 
indicated that these protons were also oriented towards each other. While an NOE signal 
between H-23 and H-8b was observed, any ambiguity about the orientation of the C-8 
protons was dismissed due to a lack of correlations between Me-16 and the diasteriotopic 
protons with opposing orientation (H-8a, H-5a, and H-26).  The Relative stereochemistry 
for the whole molecule could not be assigned due to the existence of two epimers, which 
were structurally consistent with the observed NOES. Due to the prevalence of 
































































The discovery of 1 represents a significant contribution to the study of natural 
products in light of the unprecedented structural diversity demonstrated by this 
compound. While instances of analogous vinyl iodine moieties have been reported in 
polyacetylenes (15) (16) and polyhalogenated furanones (12-14) isolated from 
Placospongia sp. (marine sponge), and Delisea pulchra  (red alga) respectively 47, 48, 1 is 
distinguished by two exocylic iodinated olefins. Curiously, the aliphatic ring systems of 1 
maintained notable structural similarities as demonstrated by: the E configuration and 
identical molecular orientation of both olefins towards the benzoate (Figure 9) and 
analogous sites of bromination on C-23 and C-14.  
             
 
Figure 10 – Structurally related natural products from Calliphycus sp (1-11); reported examples 




























































These similar structural units differed primarily in the proposed relative 
stereochemistry and retention of the isoprene head (Me-25 & Me-26) in the “C” ring.  In 
comparison to the closely related nonmacrolide diterpene shikimates from Callophycus 
sp., 1 was further differentiated by the retention of the phenolic moiety, which was 
generally functionalized into 3, 5 and 7 membered heterocycles. 41 40 Given the irregular 
nature of this structure, 1 was found to be the first example of a natural product with 
these detailed functionalizations.  
Serving as evidence of a common biosynethic origin, 1 was found to conserve the 
C27  skeleton indicative of other diterpene shikimates associated with Callophycus sp.40, 41 
The structural similarity of 1 and callophycoic acid E (9) further corroborated this 
hypothesis.40   Based on the R, R, R, S, S epimer of 1, biosynthesis of diiodcallophycoic 
acid (1) commenced with the alkylation of benzoic acid via electrophilic aromatic 
substitution with geranylgeranyl diphospate (GGP) as proposed in  (Figure 11 ).49, 40, 39, 45  
Bromination  and subsequent cyclizations of the diterpene-benzoate substrate were 







Figure 11 – Proposed biosynthetic scheme for the R, R, R, S, S confirmation of 1  
The addition of iodine(s) to the exocyclic olefin utilized a similar oxidative mechanism, 
followed by elimination reactions or direct deprotonation of the iodonium three 
membered transition state(s). The formation of electrophilic halogens (e.g. Br+ and  Cl+ ) 
in the biosynthesis of terpene based natural products has been attributed largely to 
vanadium haloperoxidases, hypothesized to additionally facilitate the oxidation of  
iodine.50, 52, 53   
Based on the proposed R,R,R,S,S epimer, 1 could represent a notable exception to 
the otherwise ubiquitous trend of enantioselectivity as seen in 9, 10 and 11. 36 Based on 
the proposed biosynthetic mechanism for these molecules 36, the preferential formation of 

















































intramolectular nucleophilic substitution by terpenoid olefins and subsequent inversion of 
configuration. 54 While the all R molecule is possible, such a finding would be equally 
unprecedented in related diterpene shikimates. 41 40 In light of the observed structural 
novelty of 1, further investigations into biosynthetic origins of this molecule could result 
in a host of equally diverse natural products.  
Diiodocallophycoic acid (1) demonstrated confounding biological activity, 
potentially alluding to the interaction of additional medicinally potent components. 
Unreported preliminary MRSA screening of crude algal extracts from G-0807 containing 
1 indicated an MIC of 3.9 µg/mL, equivalent to that of the pure compound (Table 2). 
This finding was troubling given that the biological activity of a mixture should increase, 
as the active component is concentrated through purification. Based on these findings, the 
possibility of a synergist constituent lost during fractionation should be considered and 
further explored.55 Alternatively, extracts from G-0807 are known to contain 
bromophycoic acid (A), which was reported to elicit notable potency against MRSA 
(MIC of 1.6 µg/mL), potentially skewing the preliminary screening.41  
In light of the moderate and confound biological activity of 1 compared to 
currently marketed therapeutics for both MRSA and VREF, new sources of antibiotics 
are still necessary.56, 57 Further investigations into the chemical diversity of marine 
environments remain a pivotal resource in combating human illness due to drug resistant 
bacterial infections. The Fijian ecosystem has been distinguished as source of structurally 
novel and biologically active families of natural products as demonstrated by members of 
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